Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a formal notice to stock exchanges under SEBI LODR Regulation 30, informing of an upcoming investor/analyst conference event. It does not contain any financial results, minutes, presentation materials, or transcripts—merely a compliance announcement. There is no indication of a full report being attached or published. As such, it is a general regulatory filing (fallback category).
2026-05-20 English
Intimation of Conference Call
Regulatory Filings Classification · 80% confidence The document is an intimation under Regulation 30 of the SEBI (LODR) Regulations notifying stock exchanges about an upcoming investor/analyst meeting. It does not contain financial results, transcripts, or substantive report content but is a routine compliance announcement. This falls under general regulatory filings (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a compliance announcement under Regulation 30 of SEBI (LODR) Regulations notifying the stock exchanges of an upcoming earnings conference call. It contains no actual financial results or presentation materials, but rather a regulatory intimation/notice. This fits the definition of a general regulatory filing (RNS) rather than an earnings release, transcript, or report itself.
2026-05-20 English
This is to inform you that the Earnings Conference Call for Investors and Analysts has been scheduled on Tuesday, May 26, 2026 at 4:00 P.M. (IST) to discuss the Company''s Q4 FY26 Financial Results.
Regulatory Filings Classification · 71% confidence The document is a notice under SEBI LODR Regulation 30 informing exchanges and investors of the scheduling and invitation to an earnings conference call for Q4 FY26. It does not contain financial results, transcripts, or substantive report content but is rather a regulatory announcement of a call. There is no dedicated category for “conference call invitations,” so under the fallback hierarchy, this is a general regulatory filing. Therefore, it should be classified as RNS.
2026-05-20 English
The Board Meeting to be held on 18/05/2026 has been revised to 25/05/2026 The meeting of the Board of Directors of the Company has been rescheduled to May 25, 2026
Regulatory Filings Classification · 85% confidence The document is a regulatory intimation under SEBI Listing Obligations (Regulation 29) to stock exchanges, notifying the postponement and rescheduling of a board meeting and related trading window closure. It contains no financial statements, no executive management changes, no report attachments, and is not an earnings release or AGM material. This is a routine regulatory announcement that does not fit any more specific category, so it falls under the generic Regulatory Filings (RNS) category.
2026-05-14 English
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The Audited Financial Results ....
Regulatory Filings Classification · 80% confidence The document is a formal intimation under SEBI Listing Regulations notifying a scheduled Board meeting date to consider and approve audited financial results and dividends. It does not itself contain financial data, changes in board/management, or report attachments; rather it is a regulatory compliance announcement. This fits the catch-all “Regulatory Filings (RNS)” category.
2026-05-11 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.